RHA Redensity Logo

Fined-tuned finish for moderate to severe dynamic perioral rhytids

The first and only FDA-approved filler for injection into both the superficial dermis and dermis to treat dynamic perioral rhytids.

May be appropriate for patients who:
  • Need correction with a superficially placed filler in the dermis
  • Desire a natural look and feel without unwanted heaviness

Results that last up to

12 months*

Results that last up to 12 months*

Patient was treated with 0.3 mL RHA Redensity™ in perioral rhytids; 1.9 mL RHA® 3, including 1.0 mL in nasolabial folds, 0.5 mL in marionette lines, and 0.4 mL in oral commissures; and 1.6 mL RHA® 4 in the nasolabial fold area. Images captured before and two weeks after treatment. Results may vary.

*Clinical effectiveness and safety were demonstrated in a 12-month clinical trial for the treatment of moderate to severe perioral rhytids.


Indicated for injection into the dermis and superficial dermis of the face, for the correction of moderate to severe dynamic perioral rhytids in adults 22 or older

  • Thin gauge needle (30 G x ½)
  • Inserted into superficial dermis or dermis using serial puncture, linear threading or fanning, raising a wheal with needle bevel at 5° to 15° angle to the skin surface
RHA Redensity injection at the superficial dermis compared to the other gels